Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)Symptoms, Doctors, Treatments, Advances & More
Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL) Overview
Learn About Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Stanford University
Ranjana Advani is an Oncologist practicing medicine in Palo Alto, California. She has been practicing medicine for over 44 years. Dr. Advani is rated as an Elite provider by MediFind in the treatment of Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL). She is also highly rated in 26 other conditions, according to our data. Her clinical expertise encompasses Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, and Tissue Biopsy.
Kerry Savage practices practicing medicine in Vancouver, Canada. Savage is rated as an Elite expert by MediFind in the treatment of Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL). They are also highly rated in 17 other conditions, according to our data. Their clinical expertise encompasses Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, Non-Hodgkin Lymphoma, and Bone Marrow Transplant.
UChicago Medicine River East
Sonali Smith is a Hematologist and an Oncologist practicing medicine in Chicago, Illinois. Dr. Smith is rated as a Distinguished provider by MediFind in the treatment of Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL). She is also highly rated in 25 other conditions, according to our data. Her clinical expertise encompasses Non-Hodgkin Lymphoma, Follicular Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Smith is board certified in Medical Oncology and Practicing Since2001. Dr. Smith is currently accepting new patients.
Summary: This phase II trial compares mosunetuzumab to the usual treatment (rituximab) for improving survival in patients with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). Rituximab and mosunetuzumab are monoclonal antibodies. They bind to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cel...
Objective: * To develop the data collection infrastructure required to prospectively collect longitudinal electronic patient-reported outcomes (PROs) survey instruments in adult and pediatric patients diagnosed with NLPHL. Secondary Objective: * To examine differences in baseline and longitudinal changes in PROs based on disease characteristics, disease status, and treatment strategies among adult and pediat...

